CCM
IGMS

Coldstream Capital Management’s IGM Biosciences IGMS Stock Holding History

Coldstream Capital Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,626
Closed -$3.02K – 2154
2025
Q1 		$3.02K Buy
+2,626
New +$4.88K ﹤0.01% 2875

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Coldstream Capital Management's IGMS Position: Q2 2025 in Review

Coldstream Capital Management sold out of IGM Biosciences (IGMS) in Q2 2025, closing a stake of 2,626 shares — an estimated $3.02K sold.

Coldstream Capital Management first reported a position in IGMS in Q1 2025 and held it in 1 quarter. The position peaked at $3.02K in Q1 2025. 66 funds tracked by Wall St. Rank hold IGMS as of Q2 2025.

  • Coldstream Capital Management reported no remaining IGM Biosciences position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 2,626 IGM Biosciences shares in Q2 2025, an estimated $3.02K.
  • Coldstream Capital Management first reported a position in IGM Biosciences in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's IGM Biosciences position peaked at $3.02K in Q1 2025.
  • 66 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.